Controlled Inhibition of the Mesenchymal Stromal Cell Pro-inflammatory Secretome via Microparticle Engineering
Ranganath, Sudhir H.
Karp, Jeffrey M.
Inamdar, Maneesha S.
MetadataShow full item record
CitationRanganath, Sudhir H., Zhixiang Tong, Oren Levy, Keir Martyn, Jeffrey M. Karp, and Maneesha S. Inamdar. 2016. “Controlled Inhibition of the Mesenchymal Stromal Cell Pro-inflammatory Secretome via Microparticle Engineering.” Stem Cell Reports 6 (6): 926-939. doi:10.1016/j.stemcr.2016.05.003. http://dx.doi.org/10.1016/j.stemcr.2016.05.003.
AbstractSummary Mesenchymal stromal cells (MSCs) are promising therapeutic candidates given their potent immunomodulatory and anti-inflammatory secretome. However, controlling the MSC secretome post-transplantation is considered a major challenge that hinders their clinical efficacy. To address this, we used a microparticle-based engineering approach to non-genetically modulate pro-inflammatory pathways in human MSCs (hMSCs) under simulated inflammatory conditions. Here we show that microparticles loaded with TPCA-1, a small-molecule NF-κB inhibitor, when delivered to hMSCs can attenuate secretion of pro-inflammatory factors for at least 6 days in vitro. Conditioned medium (CM) derived from TPCA-1-loaded hMSCs also showed reduced ability to attract human monocytes and prevented differentiation of human cardiac fibroblasts to myofibroblasts, compared with CM from untreated or TPCA-1-preconditioned hMSCs. Thus, we provide a broadly applicable bioengineering solution to facilitate intracellular sustained release of agents that modulate signaling. We propose that this approach could be harnessed to improve control over MSC secretome post-transplantation, especially to prevent adverse remodeling post-myocardial infarction.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27662152
- HMS Scholarly Articles